Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
about
Phase 2 study of weekly bortezomib in mantle cell and follicular lymphomaProteasome inhibitors in the treatment of multiple myelomaSmall molecule inhibitors in acute myeloid leukemia: from the bench to the clinicClinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function.Efficacy and safety of reduced-intensity induction therapy with a bortezomib-based regimen in elderly patients with multiple myeloma.The future of proteasome inhibitors in relapsed/refractory multiple myeloma.Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902).Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma.Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myeloma.
P2860
Q33669018-CF755D1C-0583-41A0-B4CF-4DFB85C43EADQ34611676-1A6C724B-EA18-4AE2-A76A-68360C9F2DEAQ34817365-6D16BC20-906A-4CDF-A41B-E5DB6757F8DAQ36057877-82087FB8-B3DF-41E0-92DD-8594B3ED337BQ36544872-8742DD46-E637-41A0-BF21-9F4EE56CCAA4Q37058114-AB5FC486-5115-43AF-A71E-368B4CF8597BQ37587057-EE3A1DF7-B344-49F1-B2D9-55C0C126A054Q37702765-1726F67B-08C5-4D91-A88E-2616B3317F7EQ38095968-C5E98FFD-092A-4C6E-A04F-75B3E663F78BQ38246060-0A6A6DF1-469E-4114-B6BC-8D30DB2F98E1Q40818284-4BAF66BF-8F39-4240-9292-14F5DAC7E3C1Q43254054-CCA1EB80-43B8-474F-9A0C-F91DC16D540EQ46004582-1E55EDA0-4C33-4633-9C20-36FFE4BB837D
P2860
Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Weekly treatment with bortezom ...... Pearl Cancer Research Network.
@ast
Weekly treatment with bortezom ...... Pearl Cancer Research Network.
@en
type
label
Weekly treatment with bortezom ...... Pearl Cancer Research Network.
@ast
Weekly treatment with bortezom ...... Pearl Cancer Research Network.
@en
prefLabel
Weekly treatment with bortezom ...... Pearl Cancer Research Network.
@ast
Weekly treatment with bortezom ...... Pearl Cancer Research Network.
@en
P2093
P356
P1433
P1476
Weekly treatment with bortezom ...... Pearl Cancer Research Network.
@en
P2093
Cindy Farley
David R Spigel
F Anthony Greco
Jeremy Hon
John Barton
Marshall Schreeder
P304
P356
10.1002/CNCR.23606
P407
P577
2008-08-01T00:00:00Z